LTRN Lantern Pharma Inc.

8.96
-0.24  -3%
Previous Close 9.2
Open 9.15
52 Week Low 8.31
52 Week High 23.5
Market Cap $100,242,742
Shares 11,187,806
Float 8,133,395
Enterprise Value $29,336,246
Volume 29,494
Av. Daily Volume 67,537
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
LP-300
Non-small cell lung cancer (NSCLC)
Phase 2
Phase 2
Phase 2 trial planned for 4Q 2021.
LP-100
Hormone-refractory prostate cancer (MHRPC)
Phase 2
Phase 2
Phase 2 trial ongoing.
LP-184
Glioblastoma(GBM)
Phase 1/2
Phase 1/2
Phase 1/2 to be initiated late 2021, noted November 1, 2021.
LP-184
Pancreatic cancer
Phase 1
Phase 1
IND and Phase 1 to be initiated late 2021, noted November 1, 2021.

Latest News

  1. Lantern Pharma Announces Share Repurchase Program

    DALLAS, Nov. 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of September 30, 2021, the Company had approximately $73.8 million…

    DALLAS, Nov. 22, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of September 30, 2021, the Company had approximately $73.8 million of cash, cash equivalents and marketable securities. The Company had approximately 11.2 million shares of common stock outstanding as of October 29, 2021.

    "Initiating a share repurchase program at this time is in line with our ongoing focus on creating value for our stockholders, which we are committed to," stated Panna Sharma, CEO and President of Lantern Pharma Inc. "It also demonstrates our confidence in advancing our clinical pipeline and our growing RADR® A.I. platform — Lantern is capitalized to achieve its upcoming clinical milestones. In light of our strong balance sheet, the board has decided to implement the share repurchase program enabling Lantern to opportunistically return value to its stockholders."

    The timing, amount of shares repurchased and prices paid for the stock under this program will depend on market conditions as well as corporate and regulatory limitations, including blackout period restrictions. The repurchase program does not obligate the Company to acquire any particular amount of shares, and the repurchase program may be suspended or discontinued at any time at the Company's discretion.

    About Lantern Pharma

    Lantern Pharma Inc. (NASDAQ:LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com  and Twitter @lanternpharma.

    About RADR®

    RADR® or Response Algorithm for Drug Positioning & Rescue, is Lantern's proprietary integrated A.I. platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine-learning. RADR® is used to provide mechanistic insights about drug-tumor interactions, predict the potential response of cancer types and subtypes to existing drugs and drug candidates, and uncover patient groups that may respond to potential therapies being developed by Lantern and its collaborators.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    CONTACT:

    Investor Relations

    David Waldman, Crescendo Communications, LLC



    212-671-1021

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-share-repurchase-program-301429876.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  2. Lantern Pharma to Host Virtual KOL Event on the Potential Treatment of Pancreatic Cancer with Drug Candidate LP-184 on November 18th, World Pancreatic Cancer Day

    DALLAS, Nov. 12, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it will host a virtual Key Opinion Leader (KOL) event regarding the potential treatment of pancreatic cancer utilizing Lantern Pharma's drug candidate LP-184, on World Pancreatic Cancer Day, Thursday, November 18th at 12:00 pm EST.

    The event will be cohosted by:

    • Dr. Igor Astsaturov, an established, NCI-funded, physician scientist and co-leader of the Marvin & Conchetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center
    • Dr. Ira Sharp, retired internal medicine specialist, as well as a pancreatic cancer survivor and cancer patient advocate
    • Dr. Kishor G. Bhatia, Chief Scientific Officer of Lantern Pharma

    The event will feature discussions on the recent advances of LP-184, a PTGR1-activated small molecule that leverages DNA repair deficiency to selectively eradicate pancreatic cancers, and potential clinical uses of LP-184 in an upcoming Phase I clinical trial.

    Lantern Pharma's Virtual KOL Event details are as follows:

    Pancreatic cancer is the fourth leading cause of cancer deaths in the United States with a five-year survival rate of 7.9% and a 10-year survival rate of just 1%. GLOBOCAN estimates that for pancreatic cancer there are approximately 490,000 new cases of pancreatic cancer globally on an annual basis, with over 62,000 of those cases occurring in North America. Due to the late onset of symptoms, patients are often diagnosed after the cancer has progressed to locally advanced or metastatic stages of the disease. LP-184 is designed to target a specific subset of pancreatic cancer patients that are genetically defined, which has the potential to increase beneficial therapeutic options for patients and may ultimately improve survival for those with this cancer.

    LP-184 is in pre-clinical development for several targeted indications in cancer, including pancreatic cancer and glioblastoma. LP-184 preferentially damages DNA in cancer cells that over-express certain biomarkers or that harbor mutations in DNA repair pathways. LP-184 was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer, and also for the treatment of glioblastoma multiforme (GBM) and other malignant gliomas.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com  and Twitter @lanternpharma.

    About RADR®

    RADR® or Response Algorithm for Drug Positioning & Rescue, is Lantern's proprietary integrated A.I. platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine-learning. RADR® is used to provide mechanistic insights about drug-tumor interactions, predict the potential response of cancer types and subtypes to existing drugs and drug candidates, and uncover patient groups that may respond to potential therapies being developed by Lantern and its collaborators.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators in the area of pancreatic cancer may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    CONTACT:

    Investor Relations

    David Waldman, Crescendo Communications, LLC



    212-671-1021

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-host-virtual-kol-event-on-the-potential-treatment-of-pancreatic-cancer-with-drug-candidate-lp-184-on-november-18th-world-pancreatic-cancer-day-301423103.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  3. Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Glioblastoma Accepted for Presentation at the Society for Neuro-Oncology 2021 Annual Meeting

    DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in person and virtually from November 18-21, 2021. The abstract is available online on the SNO website.

    …

    DALLAS, Nov. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-184 in glioblastoma multiforme (GBM) regardless of MGMT status has been accepted as a virtual poster at the upcoming 26th Society for Neuro-Oncology (SNO) Annual Meeting, which is being held in person and virtually from November 18-21, 2021. The abstract is available online on the SNO website.

    Abstract Title: LP-184, a novel alkylating agent, is effective in Glioblastoma

    Abstract ID: EXTH-16

    Submission type: Adult

    Abstract Tumor Type: Glial Tumors

    Abstract Category: Preclinical Experimental Therapeutics

    Poster Session Date & Time: Friday, November 19, 2021, 7:30 PM - 9.30 PM EST

    Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma

    The abstract submitted by Lantern Pharma and researchers at The Kennedy Krieger Institute affiliated with Johns Hopkins School of Medicine describes work demonstrating promising efficacy of LP-184 in multiple in vitro and in vivo glioblastoma models. The abstract also highlights the increased efficacy of LP-184 in MGMT unmethylated GBM, an area of large unmet clinical need, as well as the predicted synthetic lethality of LP-184 in GBM with DNA damage repair deficiencies such as decreased expression of nucleotide excision repair components ERCC3/6. The poster displays the favorable blood brain barrier crossing properties of LP-184 evaluated in vivo, suggesting that the maximum brain concentration achieved after a single intravenous infusion of LP-184 in mice is greater than that required for growth inhibition of sensitive GBM cells. These findings identify LP-184 as a promising new alkylating agent and support its further development for GBM therapy.

    Electronic poster presentation files will be captured electronically (in PDF) prior to the meeting and available on the mobile meeting app, website and onsite. Accepted abstracts will be published as a proceedings supplement in Neuro-Oncology, the official journal of the SNO after the completion of the meeting.

    LP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that overexpress certain biomarkers and is therefore lethal in tumors that harbor mutations in DNA repair pathways or have deficiency in these pathways because of low expression of genes required for DNA repair. LP-184 is being developed for several targeted central nervous system cancer indications, including glioblastoma. LP-184 has recently been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of malignant gliomas, as well as pancreatic cancer.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.

    About RADR®

    RADR® or Response Algorithm for Drug Positioning & Rescue, is Lantern's proprietary integrated A.I. platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine-learning. RADR® is used to provide mechanistic insights about drug-tumor interactions, predict the potential response of cancer types and subtypes to existing drugs and drug candidates, and uncover patient groups that may respond to potential therapies being developed by Lantern and its collaborators.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    CONTACT:

    Investor Relations

    David Waldman, Crescendo Communications, LLC



    212-671-1021

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-184-in-glioblastoma-accepted-for-presentation-at-the-society-for-neuro-oncology-2021-annual-meeting-301422140.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  4. Lantern Pharma to Participate in Two Upcoming Investor Conferences

    DALLAS, Nov. 9, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that management will be participating in two upcoming investor conferences.

    Q4 Investor Summit

    Panna Sharma, President and Chief Executive Officer of Lantern Pharma, is scheduled to present virtually at the Q4 Investor Summit on Tuesday, November 16th at 11:00 am Eastern Time. The presentation will be webcast live and can be accessed at: https://us06web.zoom.us/webinar/register/WN_I0YvAeqyTBeEwPGkhRCYYw and on the investor relations section of Lantern's website at https://ir.lanternpharma.com/. Mr. Sharma will also be participating in one-on-one meetings with qualified members of the investor community throughout the conference.

    To register for the conference, please visit www.investorsummitgroup.com.

    Torrey Hills Capital 6th Annual Emerging Growth Conference

    David Margrave, Chief Financial Officer of Lantern Pharma will be participating in one-on-one meetings with investors throughout the Torrey Hills Conference being held on November 17, 2021 at the Morgan Run Club and Resort in Rancho Santa Fe, California.

    Please contact Anthony Allocca at  if interested in arranging a one-on-one meeting with Mr. Margrave during the event.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    CONTACT:

    Investor Relations

    David Waldman, Crescendo Communications, LLC



    212-671-1021

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-participate-in-two-upcoming-investor-conferences-301419818.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
  5. Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting

    DALLAS, Nov. 4, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Lantern Pharma's abstract on the effectiveness of LP-284 in hematologic cancers has been accepted as a poster at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, which is being held in-person and virtually from December 11 – 14, 2021. The abstract is available online on the ASH website.

    Abstract Title: The Positive Enantiomer of a Novel Chiral DNA Alkylating Agent Exhibits Nanomolar Potency in Hematologic Cancers

    Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster III

    Abstract Number: 3991

    Poster Session Date & Time: Monday, December 13, 2021, 6:00 PM - 8:00 PM

    Presenter: Jianli Zhou, Ph.D., Lantern Pharma

    LP-284 is a fully synthetic molecule belonging to the new generation of acylfulvenes, a family of naturally derived anti-cancer drug candidates. While LP-184 shows potency in solid cancer, LP-284 was primarily developed as an analogue which shows selective efficacy against hematologic cancer. LP-284 is currently being evaluated for activity in a wide spectrum of hematological cancers.

    Together with the work of collaborators, the roadmap to advancement of LP-284 to the clinic includes identification and validation of target indications, response gene signature development leading to IND-enabling pharmacokinetic profiling, and tolerability and dose range finding studies followed by clinical protocol development.

    About Lantern Pharma

    Lantern Pharma (LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR® A.I. platform and machine learning to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes. More information is available at: www.lanternpharma.com and Twitter @lanternpharma.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 10, 2021. You may access our Annual Report on Form 10-K for the year ended December 31, 2020 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

    CONTACTS:

    Investor Relations

    David Waldman, Crescendo Communications, LLC



    212-671-1021

    Public Relations

    Nicholas Koulermos, Vice President – 5W Public Relations



    646-843-1812

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-announces-abstract-on-effectiveness-of-lp-284-in-hematologic-cancers-accepted-for-presentation-at-the-63rd-american-society-of-hematology-ash-annual-meeting-301416654.html

    SOURCE Lantern Pharma

    View Full Article Hide Full Article
View All Lantern Pharma Inc. News